ClinicalTrials.gov term: Small Cell Lung Carcinoma
51 trials changed in the last 30 days: 0 stopped, 16 with notable changes, 35 with minor changes only.
Primary and study completion pushed from Apr 2026 to Apr 2027
Also in this update: Primary endpoint(s) modified
Suzhou Zelgen Biopharmaceuticals Co.,LtdPhase 1/2 NCT06283719 Registry history of NCT06283719 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Sep 30, 2026 to Jul 20, 2027
Also in this update: Study completion pushed from Dec 30, 2026 to Feb 20, 2028
Daiichi SankyoPhase 1/2 NCT06362252 Registry history of NCT06362252 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Dec 31, 2026 to Apr 20, 2030
Also in this update: Enrollment increased: 470 → 540 participants; Study completion pushed from Mar 21, 2028 to Jul 22, 2030
SystImmune Inc.Phase 1 NCT05983432 Registry history of NCT05983432 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Sep 2026 to Sep 2030
Also in this update: Enrollment increased: 12400 → 14500 participants; Study completion pushed from Dec 2027 to Sep 2031
AIO-Studien-gGmbHNot specified NCT02622581 Registry history of NCT02622581 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Sep 2026 to Sep 2028
Also in this update: Enrollment changed: None → 15000
Massachusetts General HospitalNot specified NCT00471978 Registry history of NCT00471978 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Interventions modified
Radiopharm Theranostics, LtdPhase 1/2 NCT07189871 Registry history of NCT07189871 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Trial completed; Primary completion date changed from estimate of Aug 2030 to May 6, 2026
Arbeitsgemeinschaft medikamentoese TumortherapieNot specified NCT04654364 Registry history of NCT04654364 on ClinicalTrials.gov (opens the registry)
Sponsor changed: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair to Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair
Also in this update: Primary completion pushed from Sep 18, 2026 to Dec 18, 2026; Study completion pushed from Oct 28, 2026 to Jun 28, 2027
Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB ChairPhase 2/3 NCT07145333 Registry history of NCT07145333 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Start date changed from estimate of Sep 2026 to Oct 7, 2026
Shanghai Hengrui Pharmaceutical Co., Ltd.Phase 2 NCT07798947 Registry history of NCT07798947 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Start date changed from estimate of Oct 5, 2026 to Oct 1, 2026; and 1 more change in the last 30 days
Boehringer IngelheimPhase 1/2 NCT07843940 Registry history of NCT07843940 on ClinicalTrials.gov (opens the registry)
Reclassified as terminated (was completed)
Also in this update: Results posted: Oct 9, 2026
Compass TherapeuticsPhase 1 NCT03881488 Registry history of NCT03881488 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Hangzhou DAC Biotechnology Co., Ltd.Phase 1/2 NCT07559929 Registry history of NCT07559929 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Treeline Biosciences, Inc.Phase 1 NCT07713732 Registry history of NCT07713732 on ClinicalTrials.gov (opens the registry)
Recruitment opened
National Cancer Institute (NCI)Phase 1 NCT07509034 Registry history of NCT07509034 on ClinicalTrials.gov (opens the registry)
Changed
Recruitment opened
Ohio State University Comprehensive Cancer CenterNot specified NCT07795411 Registry history of NCT07795411 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 150 → 238 participants
Also in this update: Interventions modified; Trial arms changed: 2 → 10
NiKang Therapeutics, Inc.Phase 1 NCT06586957 Registry history of NCT06586957 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Sep 30, 2026 to Aug 20, 2026
Hansoh BioMedical R&D CompanyPhase 3 NCT06498479 Registry history of NCT06498479 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Dec 2028 to Apr 2029
Also in this update: Study completion pushed from Mar 2029 to Jul 2029
BioNTech SEPhase 3 NCT06712355 Registry history of NCT06712355 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Primary and study completion pushed from Oct 30, 2027 to Feb 5, 2028
Pharmacosmos A/SPhase 4 NCT05874401 Registry history of NCT05874401 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of May 26, 2027 to Sep 9, 2026
Bristol-Myers SquibbPhase 1 NCT06799286 Registry history of NCT06799286 on ClinicalTrials.gov (opens the registry)
Completed without a posted recruiting period
Also in this update: Primary completion date changed from estimate of Sep 1, 2030 to Aug 29, 2026
Shanghai Pulmonary Hospital, Shanghai, ChinaPhase 2 NCT06648200 Registry history of NCT06648200 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Sep 30, 2026 to Dec 15, 2026
Boehringer IngelheimPhase 1 NCT05963867 Registry history of NCT05963867 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jun 2027 to Oct 31, 2027
Pharmacosmos A/SPhase 3 NCT07473128 Registry history of NCT07473128 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from May 10, 2029 to Aug 10, 2029
AmgenPhase 2 NCT06745323 Registry history of NCT06745323 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
SCRI Development Innovations, LLCPhase 2 NCT06773910 Registry history of NCT06773910 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 155 → 165 locations
Zai Lab (Shanghai) Co., Ltd.Phase 3 NCT07218146 Registry history of NCT07218146 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 19 → 27 locations
Avenzo Therapeutics, Inc.Phase 1/2 NCT07038343 Registry history of NCT07038343 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 38 → 41 locations
Zai Lab (Shanghai) Co., Ltd.Phase 1 NCT06179069 Registry history of NCT06179069 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 1 → 6 locations
BeOne MedicinesNot specified NCT07652736 Registry history of NCT07652736 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 57 → 61 locations
And 1 more change in the last 30 days
PfizerPhase 2 NCT07476287 Registry history of NCT07476287 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 65 → 71 locations
AbbViePhase 3 NCT07365241 Registry history of NCT07365241 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 41 → 55 locations
European Organisation for Research and Treatment of Cancer - EORTCNot applicable NCT04790253 Registry history of NCT04790253 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 17 → 21 locations
Astellas Pharma Global Development, Inc.Phase 1/2 NCT07488676 Registry history of NCT07488676 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 3 → 7 locations
Avacta Life Sciences LtdPhase 1 NCT07454642 Registry history of NCT07454642 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 3 → 6 locations
Alliance Foundation Trials, LLC.Phase 2 NCT07149363 Registry history of NCT07149363 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from Sep 5, 2031 to Jul 14, 2031
Also in this update: Primary completion moved earlier from Apr 6, 2028 to Aug 17, 2027
Bristol-Myers SquibbPhase 3 NCT06646276 Registry history of NCT06646276 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Dec 31, 2026 to Nov 30, 2027
Also in this update: Primary completion date changed from estimate of Dec 31, 2026 to Nov 30, 2025
Klus Pharma Inc.Phase 1/2 NCT04152499 Registry history of NCT04152499 on ClinicalTrials.gov (opens the registry)
Start date moved earlier from Apr 13, 2026 to Nov 7, 2025
Boehringer IngelheimPhase 3 NCT07472517 Registry history of NCT07472517 on ClinicalTrials.gov (opens the registry)
Interventions modified
GlaxoSmithKlinePhase 3 NCT07099898 Registry history of NCT07099898 on ClinicalTrials.gov (opens the registry)
Primary and study completion moved earlier from Apr 27, 2029 to Feb 15, 2029
Merck Sharp & Dohme LLCPhase 1/2 NCT06780137 Registry history of NCT06780137 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Sep 18, 2026 to Sep 17, 2027
National Cancer Institute (NCI)Phase 1 NCT02589522 Registry history of NCT02589522 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 1 → 4 locations
Nantes University HospitalNot applicable NCT06481813 Registry history of NCT06481813 on ClinicalTrials.gov (opens the registry)
Start date pushed from Sep 29, 2026 to Oct 19, 2026
Boehringer IngelheimPhase 1/2 NCT07707895 Registry history of NCT07707895 on ClinicalTrials.gov (opens the registry)
Start date changed from estimate of Sep 30, 2026 to Sep 17, 2026
Puma Biotechnology, Inc.Phase 2 NCT07465757 Registry history of NCT07465757 on ClinicalTrials.gov (opens the registry)
Interventions modified
PfizerPhase 1 NCT03460977 Registry history of NCT03460977 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from May 1, 2031 to Sep 2, 2030
Also in this update: Primary completion date changed from estimate of Sep 1, 2026 to Mar 2, 2026
Mayo ClinicPhase 2 NCT04607954 Registry history of NCT04607954 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Aug 19, 2026 to Sep 2, 2027
National Cancer Institute (NCI)Phase 2 NCT04079712 Registry history of NCT04079712 on ClinicalTrials.gov (opens the registry)
Registry marked status Unknown (sponsor has not verified the record since Jun 2024); last known: Not Yet Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3 NCT06469879 Registry history of NCT06469879 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
Hunan Province Tumor HospitalPhase 2 NCT06497543 Registry history of NCT06497543 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Dec 2023); last known: Recruiting
Nanfang Hospital, Southern Medical UniversityPhase 2 NCT06177925 Registry history of NCT06177925 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Hunan Province Tumor HospitalPhase 2 NCT04951947 Registry history of NCT04951947 on ClinicalTrials.gov (opens the registry)
Changed
Registry verification sweep
Changed
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-10-07 | NCT07864207 Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With… | IDP Discovery Pharma S.L. new | Phase 1/2 |
| 2026-09-15 | NCT07819591 Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC | Shaodong Hong new | Phase 2 |
| 2026-09-11 | NCT07815223 A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in… | Yantai Yuhuangding Hospital new | Phase 2 |
| 2026-09-02 | NCT07798947 A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in… | Shanghai Hengrui Pharmaceutical Co., Ltd. new | Phase 2 |
| 2026-08-07 | NCT07752875 A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53… | LG Chem new | Phase 1/2 |
| 2026-08-03 | NCT07742800 Multi-Omics Prediction of Radiation Lung Injury in Immunotherapy-Treated Lung Cancer… | HAN GUANG new | |
| 2026-07-27 | NCT07728955 A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of… | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University new | Phase 3 |
| Early Phase 1 | 6 | |
| Phase 1 | 81 | |
| Phase 1/2 | 75 | |
| Phase 2 | 171 | |
| Phase 2/3 | 6 | |
| Phase 3 | 57 | |
| Phase 4 | 6 |
National Cancer Institute (NCI) (21) · Amgen (14) · AstraZeneca (12) · Boehringer Ingelheim (9) · Peking University Cancer Hospital & Institute (9) · Shanghai Pulmonary Hospital, Shanghai, China (9) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (8) · Sichuan University (8) · Sichuan Baili Pharmaceutical Co., Ltd. (7) · Henan Cancer Hospital (6)